USPTO Examiner COLEMAN BRENDA LIBBY - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19044731METHOD OF SYNTHESIZING TESTOSTERONE-BASED THIAZOLIDINONE DERIVATIVESFebruary 2025May 2025Allow310YesNo
18820993PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTAugust 2024February 2025Allow510NoNo
18832297PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI- COMPONENT MATERIALJuly 2024April 2025Allow910NoNo
18832315PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6 COMPRISING FISHING NETSJuly 2024April 2025Allow910NoNo
18745710CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSJune 2024September 2025Abandon1520NoNo
18655985MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYEMay 2024February 2026Allow2110NoNo
18645972CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALTApril 2024July 2024Allow310NoNo
186116858-((4-HYDROXY-3-METHOXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDMarch 2024September 2024Allow610NoNo
18592020MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEFebruary 2024March 2026Abandon2410NoNo
18586019NUCLEAR TRANSPORT MODULATORS AND USES THEREOFFebruary 2024November 2025Allow2110NoNo
18584672PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTFebruary 2024February 2025Allow1210NoNo
18584177PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTFebruary 2024March 2025Allow1310NoNo
18581677PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASESFebruary 2024February 2026Allow2310NoNo
18439695COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASEFebruary 2024December 2025Allow2211NoNo
18432727RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAMEFebruary 2024January 2026Abandon2310NoNo
18414104QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATESJanuary 2024January 2026Abandon2401NoNo
18411439HETEROCYCLIC COMPOUNDS AND RELATED METHODSJanuary 2024September 2025Allow2010NoNo
18405657NEUROACTIVE STEROIDS AND METHODS OF USE THEREOFJanuary 2024December 2025Allow2320NoNo
18391693REDOX ACTIVE MATERIALS, PROCESSES AND USES THEREOFDecember 2023February 2025Allow1410NoNo
18544956THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERSDecember 2023July 2025Allow1920NoNo
18542913CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) FOR USE IN SIPI RECEPTOR-ASSOCIATED DISORDERSDecember 2023March 2025Allow1510NoNo
18533894CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSDecember 2023April 2024Allow420NoNo
18530405TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORSDecember 2023July 2025Allow2021NoNo
18529334COMPOUNDS, DEVICES, AND USES THEREOFDecember 2023September 2025Allow2221NoNo
18514959INHIBITORS OF LRRK2 KINASENovember 2023June 2025Allow1820NoNo
18513229HETEROCYCLIC COMPOUNDS AS PAD INHIBITORSNovember 2023March 2025Allow1511NoNo
18389574COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOWE SYNDROMENovember 2023January 2025Allow1520NoNo
18507013THERAPEUTIC COMPOUNDS AND COMPOSITIONSNovember 2023April 2025Allow1810NoNo
183855868-(4-nitroxybenzylideneamino)naphthalene-1,3-disulfonic acid AS AN ANTIOXIDANT COMPOUNDOctober 2023January 2024Allow300NoNo
183858088-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023March 2024Allow510NoNo
18495845Oral Formulation of Clonidine and Midazolam for Sedation in Dental ProceduresOctober 2023July 2024Allow900NoNo
18493421COMPOUNDS AND PHARMACEUTICAL USES THEREOFOctober 2023September 2025Allow2221NoNo
18382896METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATESOctober 2023May 2025Abandon1810NoNo
18490596COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSIONOctober 2023November 2025Abandon2520NoNo
18489303PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSMOctober 2023July 2025Abandon2120NoNo
18486759ANTI-VIRAL COMPOUNDSOctober 2023October 2024Allow1210NoNo
18368576FLUORESCENT MATERIAL CONTAINING THIOPHENE SULFONE-OLEFIN STRUCTURAL UNIT AND PREPARATION METHOD THEREOFSeptember 2023March 2026Allow3010NoNo
18243771PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOFSeptember 2023April 2025Allow1910NoNo
18463407NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORSSeptember 2023October 2024Allow1410NoNo
18462488METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSISSeptember 2023January 2025Allow1620NoNo
18451918Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint InhibitorsAugust 2023November 2025Allow2721NoNo
18448497PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTAugust 2023August 2024Allow1310NoNo
18363933TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTSAugust 2023September 2024Allow1410NoNo
18225589Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)July 2023February 2025Abandon1910NoNo
18328865COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERSJune 2023January 2025Allow2010NoNo
18255969SYNTHESIS OF STRUCTURAL ANALOGS OF LARGAZOLE AND ASSOCIATED COMPOUNDSJune 2023October 2024Allow1620NoNo
18039129THERAPEUTIC AGENT FOR SHORT TEAR BREAKUP TIME-TYPE DRY EYE AND EYE DROPS CONTAINING SAMEMay 2023February 2026Allow3310NoNo
18323510Heterocyclic Adenosine Receptor AntagonistsMay 2023November 2024Allow1820NoNo
18196459BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORSMay 2023February 2025Allow2110NoNo
18252695IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORSMay 2023September 2025Allow2800NoNo
18445155Ibogaine-related compounds and corresponding methodsMay 2023July 2025Abandon2720NoNo
18309998COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITYMay 2023March 2026Allow3520NoNo
18250893COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR PROMOTING MUSCLE GROWTHApril 2023March 2026Allow3420NoNo
18140348BENZAZEPINE DERIVATIVESApril 2023March 2025Abandon2310NoNo
18307181RIP1K INHIBITORSApril 2023January 2025Allow2120NoNo
18135898ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USEApril 2023January 2025Abandon2110NoNo
18135499MEDICAMENT FOR TREATING COUGHApril 2023November 2024Allow1911NoNo
18301742CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSApril 2023October 2023Allow610NoNo
18300350CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSApril 2023April 2024Abandon1220NoNo
18299299PROCESS FOR THE PREPARATION OF 1-METHYL-6-[6-R2-5-METHYL-8-(METHYLAMINO)-4-[ (3AS,6AS)-5-METHYL-2,3,3A,4,6,6A-HEXAHYDROPYRROLO[2,3-C]PYRROL-1-YL]-9H-PYRIDO[2,3-B]INDOL-3-YL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID HYDROCHLORIDEApril 2023March 2026Abandon3510NoNo
18298825AGENT FOR ELEVATING NITRIC OXIDE CONCENTRATIONApril 2023August 2025Allow2800NoNo
18128603C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAMEMarch 2023April 2025Allow2421NoNo
18028840CRYSTAL FORM OF PYRROLO HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFORMarch 2023February 2026Abandon3510NoNo
18126953COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITISMarch 2023October 2024Allow1910NoNo
18028578MACROCYCLIC COMPOUNDMarch 2023December 2025Allow3310NoNo
18026309TYK2 INHIBITORS AND USES THEREOFMarch 2023March 2026Allow3610NoNo
18180997PROCESS FOR PREPARING LEVOKETOCONAZOLEMarch 2023June 2023Allow310NoNo
18119321METHODS OF TREATMENTMarch 2023August 2024Abandon1820NoNo
18024592CELL GLYCOCALYX PROTECTION EFFECT OF ANISODAMINEMarch 2023February 2026Allow3620YesNo
18114043HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOFFebruary 2023August 2025Allow2920NoYes
18041743CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFFebruary 2023February 2026Allow3620NoNo
18164974Antiviral Pyrazolopiridinone CompoundsFebruary 2023February 2025Allow2410NoNo
18162432PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDSJanuary 2023January 2025Abandon2410NoNo
18007054PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTIONJanuary 2023February 2026Allow3610NoNo
18006927STRUCTURAL ANALOGUES OF METHYLPHENIDATE AS PARKINSON'S DISEASE-MODIFYING AGENTSJanuary 2023January 2026Allow3620NoNo
18095621CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDEJanuary 2023January 2024Allow1320NoNo
18149696C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USESJanuary 2023September 2025Allow3341YesNo
18003454ISOXAZOLINE-SUBSTITUTED BENZAMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOFDecember 2022October 2025Allow3410NoNo
18087338CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFDecember 2022August 2024Allow2010NoNo
18086076MAYTANSINOID-BASED DRUG DELIVERY SYSTEMSDecember 2022June 2025Allow3020NoNo
18078511Charged Ion Channel Blockers and Methods for UseDecember 2022November 2024Abandon2310NoNo
18062896SUBSTITUTED AMINO-PYRIMIDINESDecember 2022February 2026Allow3810NoNo
18000684AMINOPYRIDINE COMPOUNDDecember 2022January 2026Allow3811NoNo
18073897METHODS OF TREATING PATIENTS SUFFERING FROM BRAIN INJURY AND METHODS OF INCREASING THE VALUE OF THE EXTENDED GLASGOW OUTCOME SCALE OF PATIENTS SUFFERING FROM BRAIN INJURYDecember 2022August 2024Allow2020YesNo
18000632DUAL KINASE-BROMODOMAIN INHIBITORSDecember 2022January 2026Abandon3810NoNo
18059838IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITYNovember 2022November 2024Allow2311NoNo
17991899SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENTNovember 2022April 2024Allow1610NoNo
17992371Antifibrotic Compounds And Related MethodsNovember 2022July 2024Allow2010NoNo
17999104COMPOSITIONS AND METHODS OF TREATMENT WITH GLUTATHIONENovember 2022September 2025Allow3410NoNo
179892375-Membered Heteroaryl Carboxamide Compounds for Treatment of HBVNovember 2022February 2024Allow1500NoNo
17988366Aceclidine Derivatives, Compositions Thereof and Methods of Use ThereofNovember 2022August 2024Allow2130NoNo
17978696COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCERNovember 2022December 2024Allow2520NoNo
17977371PHARMACEUTICAL COMPOSITIONS AND METHODSOctober 2022May 2024Allow1910NoNo
17975623APPLICATION OF ANLE138B IN DRUG FOR IMPROVING DIET-INDUCED INSULIN RESISTANCEOctober 2022March 2024Abandon1710NoNo
17973710USE OF ERGOTHIONEINE FOR EXTENDING LIFESPAN OR IMPROVING HEALTHSPANOctober 2022September 2025Allow3410YesNo
17971865COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERSOctober 2022November 2023Allow1200NoNo
17967301CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOFOctober 2022May 2024Allow1810NoNo
17967308CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOFOctober 2022May 2024Allow1810YesNo
17918607Synthesis of Vinylic Protected Alcohol IntermediatesOctober 2022June 2025Allow3210NoNo
17995886PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDSOctober 2022December 2025Allow3820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COLEMAN, BRENDA LIBBY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
31.0%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
77
Allowed After Appeal Filing
31
(40.3%)
Not Allowed After Appeal Filing
46
(59.7%)
Filing Benefit Percentile
67.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner COLEMAN, BRENDA LIBBY - Prosecution Strategy Guide

Executive Summary

Examiner COLEMAN, BRENDA LIBBY works in Art Unit 1624 and has examined 2,090 patent applications in our dataset. With an allowance rate of 72.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner COLEMAN, BRENDA LIBBY's allowance rate of 72.1% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by COLEMAN, BRENDA LIBBY receive 1.61 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COLEMAN, BRENDA LIBBY is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +16.8% benefit to allowance rate for applications examined by COLEMAN, BRENDA LIBBY. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 37.3% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 64.8% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 91.4% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 86.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.5% are granted (fully or in part). This grant rate is in the 52% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.